Rapid Screening for Olfactory Disorders in Covid-19 Infection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-08

Study Completion Date

2023-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Loss of smell is very frequently found in Europe during Covid-19 attack. This symptom was not initially expected as part of the classic symptomatology. This loss of smell mainly concerns patients with few or no symptoms, without criteria of severity and usually treated on an outpatient basis. As a result, given the unexpected occurrence of this symptom (with less awareness in the general and medical population) and the potential risk of contamination of Covid+ and anosmic subjects (due to their less symptomatic form), it is interesting to be able to propose large-scale screening for loss of sense of smell in order to preferentially direct subjects diagnosed as anosmic towards RT-PCR-type screening. In the medium term, the loss of smell seems to persist after the infectious phase, with delayed or persistent recovery, which can lead to negative psychological repercussions.

The objective is to propose large-scale screening of the general population for loss of sense of smell during a pandemic period, in order to facilitate diagnostic orientation of the population. The diagnosis of loss of smell will be carried out using a simple olfactory test in the form of an olfactory stick to be smelled.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of the Evolution of Olfactory Disorders in Patients With Persistent Loss of Smell Following COVID-19

NCT05133596

SARS-CoV-2 Acute Respiratory Disease

COMPLETED NA

Study of the Pathogenesis of Olfactory Disorders in COVID-19

NCT04366934

Coronavirus Infection Severe Acute Respiratory Syndrome Sars-CoV2

COMPLETED

Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation

NCT06482138

Covid19 Olfactory Dysfunction

RECRUITING NA

Anosmia and Covid-19

NCT05246059

Anosmia SARS CoV 2 Infection

COMPLETED NA

Olfactory Training As a Treatment for Olfactory Dysfunction Post COVID-19

NCT05384561

Hyposmia COVID-19 Parosmia +2 more

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Olfaction Disorders COVID-19 Testing

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Olfactory test

The result of the olfactory test will be compared to the result of the RT-PCR test.

Group Type EXPERIMENTAL

Olfactory test

Intervention Type DIAGNOSTIC_TEST

The olfactory test (Olfascan) is in the form of a paper stick, previously impregnated with an odorant (non-liquid). It is placed a few centimetres from the participant's nose at the time of the test. It is a single-use test, without contact with the participant.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Olfactory test

The olfactory test (Olfascan) is in the form of a paper stick, previously impregnated with an odorant (non-liquid). It is placed a few centimetres from the participant's nose at the time of the test. It is a single-use test, without contact with the participant.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject presenting himself at the covid-19 screening centre set up by the city of Nice

Exclusion Criteria

* Presence of a sensory deficit (auditory or visual) preventing the subject from answering the questions perfectly during the olfactory test.
* Subject receiving cancer chemotherapy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes